{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:59:46Z","timestamp":1792879186706,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.cgh.2017.09.027","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T18:01:37Z","timestamp":1506103297000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":203,"title":["Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis"],"prefix":"10.1016","volume":"16","author":[{"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neddie","family":"Zadeikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Calinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez S.","family":"Mantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hezode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-3537","authenticated-orcid":false,"given":"Rui Tato","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-6886","authenticated-orcid":false,"given":"Jens","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa I.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.027_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.12351","article-title":"The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: volume 2","volume":"22","author":"Hatzakis","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2017.09.027_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.09.027_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.027_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2017.09.027_bib5","series-title":"EPCLUSA (sofosbuvir and velpatasvir). Prescribing information","year":"2016"},{"key":"10.1016\/j.cgh.2017.09.027_bib6","series-title":"ZEPATIER (elbasvir\/grazoprevir). Prescribing information","year":"2016"},{"key":"10.1016\/j.cgh.2017.09.027_bib7","unstructured":"HARVONI (ledipasvir and sofosbuvir) tablets. Prescribing information. Foster City, CA: Gilead Sciences, 2015."},{"key":"10.1016\/j.cgh.2017.09.027_bib8","series-title":"VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]","year":"2016"},{"key":"10.1016\/j.cgh.2017.09.027_bib9","series-title":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C virus","year":"2017"},{"key":"10.1016\/j.cgh.2017.09.027_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL. Recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.09.027_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In\u00a0vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2017.09.027_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.09.027_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-3758(01)00077-5","article-title":"Optimally weighted, fixed sequence and gatekeeper multiple testing procedures","volume":"99","author":"Westfall","year":"2001","journal-title":"J\u00a0Stat Plan Inference"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.027_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/liv.13324","article-title":"From HCV to HBV cure","volume":"37","author":"Schinazi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2017.09.027_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5009\/gnl.2011.5.4.406","article-title":"The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors","volume":"5","author":"Kwo","year":"2011","journal-title":"Gut Liver"},{"key":"10.1016\/j.cgh.2017.09.027_bib16","doi-asserted-by":"crossref","first-page":"704912","DOI":"10.1155\/2013\/704912","article-title":"Direct-acting antivirals for the\u00a0treatment of chronic hepatitis C: open issues and future\u00a0perspectives","volume":"2013","author":"Chae","year":"2013","journal-title":"Scientific World Journal"},{"key":"10.1016\/j.cgh.2017.09.027_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.13514","article-title":"Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy","volume":"43","author":"Banerjee","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.027_bib18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.09.027_bib19","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.09.027_bib20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.09.027_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.09.027_bib22","series-title":"VOSEVI (sofosbuvir\/velpatasvir\/voxilaprevir). Prescribing information","year":"2017"},{"key":"10.1016\/j.cgh.2017.09.027_bib23","series-title":"MAVYRET (glecaprevir\/pibrentasvir). Prescribing information","year":"2017"},{"key":"10.1016\/j.cgh.2017.09.027_bib24","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In\u00a0vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2017.09.027_bib25","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2017.09.027_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"High SVR rates upon 8- or 12-week treatment with glecaprevir and pibrentasvir in patients with chronic HCV genotype 1-6 infection without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2017.09.027_bib27","unstructured":"Zeuzem S, Feld J, Wang S, et\u00a0al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493\/ABT-530 in patients with chronic HCV genotype 1 infection. The Liver Meeting, Boston, MA,\u00a02016."},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.027_bib28","first-page":"417A","article-title":"Analysis of HCV variants in the MAGELLAN-I study (part 1): ABT-493 and ABT-530 combination therapy of genotype 1-infected patients who had failed prior direct acting antiviral-containing regimens","volume":"64","author":"Ng","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.09.027_bib29","first-page":"183","article-title":"High SVR rates with ABT-493\u00a0+ ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection","volume":"64","author":"Muir","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2017.09.027_bib30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.cgh.2017.09.027_bib31","doi-asserted-by":"crossref","unstructured":"Puoti M, Foster G, Wang S, et\u00a0al. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir\/pibrentasvir: integrated e\ufb03cacy analysis of genotype 1\u20136 patients without cirrhosis. International Liver Congress, Amsterdam, Netherlands,\u00a02017.","DOI":"10.1016\/S0168-8278(17)31927-X"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651731162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651731162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:58Z","timestamp":1761542698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235651731162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S154235651731162X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.09.027","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}